Glaxo and Medicago’s Plant-Based Vaccine 75.3% Effective Against Delta Variant

- Advertisement -


Courtesy of Medicago

- Advertisement -

Canadian drug developers Medicago and GlaxoSmithKline said on Tuesday that their plant-based COVID-19 vaccine showed positive results in late trials.

- Advertisement -

the vaccine demonstrated 71% efficacy Against all variants in the Phase 3 study, the globally dominant delta variant with a higher efficacy rate of 75.3% against COVID-19 infection of any severity, the two companies said in a statement.

The new Omicron strain – which was first identified in South Africa last month – was not circulating during the study, which was carried out in more than 24,000 adults in six countries, including the US and UK.

- Advertisement -

No associated serious adverse events were reported during the study, and reactions were generally mild to moderate and transient, with symptoms lasting, on average, only one to three days.

The full results of the study will be released in a peer-reviewed publication as soon as possible. Medicago said it would seek regulatory approval from Health Canada as part of its rolling submission based on the findings.

“The results of our clinical trials show the power of plant-based vaccine manufacturing technology. If approved, we will contribute to the world’s fight against the COVID-19 pandemic with the world’s first plant-based vaccine for use in humans,” said Takashi Nagao, Chief Executive Officer of Medicago.

The Medicago vaccine uses a technology known as virus-like particles (VLPs), which mimic the structure of the coronavirus but contain no genetic material. The production of VLPs is done in plant based system.

Write to [email protected]

,

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox